Date Title Description PDF
27 Feb 2024 About Corporate Governance The Company informs about the agreements adopted by the Board of Directors Download
08 Nov 2023 On P&L The Company releases the press release related to the first nine months of 2023 financial results Download
08 Nov 2023 On P&L The Company releases the first nine months 2023 financial results presentation Download
26 Jul 2023 On P&L The Company releases the press release related to the first half 2023 financial results Download
26 Jul 2023 On P&L The Company releases the first half 2023 financial results presentation Download

Pages

Date Title Description PDF
05 Nov 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted on 3 and 4 November Download
03 Nov 2021 On business and financial situation The Company releases the first nine months 2021 financial results presentation Download
03 Nov 2021 On business and financial situation The Company releases the press release related to the first nine months 2021 financial results Download
21 Oct 2021 Liquidity and counterparty agreements Download
21 Oct 2021 On business and financial situation The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). Download

Pages

Date Title Description PDF
26 Feb 2019 Información sobre resultados ROVI releases the presentation related to the full year 2018 results Download
26 Feb 2019 Información sobre resultados ROVI releases the press release related to the full year 2018 results Download
15 Feb 2019 Others on business performance and financial information ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets Download
09 Jan 2019 Others on business performance and financial information ROVI informs about the adquisition of Falithrom® for the German market Download
08 Jan 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the fourth quarter of 2018 Download

Pages